

Timing of Cholecystectomy After Percutaneous Cholecystostomy in High-Risk Acute Cholecystitis: Early (<4 Weeks) Versus Delayed (>4 Weeks) Surgery – A Retrospective Cohort Study

¹Ricardo A. Gonzalez Jaramillo, Department of General Surgery, Hospital Central Norte, Petroleos Mexicanos (PEMEX), Mexico City, Mexico

¹Eduardo Jordan Garcia, Department of General Surgery, Hospital Central Norte, Petroleos Mexicanos (PEMEX), Mexico City, Mexico

¹Cristina Peralta Rivera, Department of General Surgery, Hospital Central Norte, Petroleos Mexicanos (PEMEX), Mexico City, Mexico

¹Carlos Javier Mata Quintero, Department of General Surgery, Hospital Central Norte, Petroleos Mexicanos (PEMEX), Mexico City, Mexico

Corresponding Author: Ricardo A. Gonzalez Jaramillo, Department of General Surgery, Hospital Central Norte, Petroleos Mexicanos (PEMEX), Mexico City, Mexico

Citation This Article: Ricardo A. Gonzalez Jaramillo, Eduardo Jordan Garcia, Cristina Peralta Rivera, Carlos Javier Mata Quintero, “Minimally Invasive Surgical Technologies: Optimizing Operating Room Efficiency”, IJHDC – January – February – 2026, Volume. – 5, Issue – 1, P. No. 13 – 19.

Open Access Article: This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Background: Percutaneous cholecystostomy (PC) is commonly used as a bridging intervention in high-risk patients with acute cholecystitis who are unsuitable for immediate surgery¹. Despite its widespread use, the optimal timing of interval cholecystectomy after PC remains unclear, with available evidence limited by retrospective design and substantial heterogeneity^{2–4}.

Methods: We conducted a single-center retrospective cohort study of adult patients with acute cholecystitis treated initially with PC between 2016 and 2025 who

subsequently underwent cholecystectomy. Patients were grouped according to the interval between PC and surgery (≤ 4 weeks vs > 4 weeks). Baseline characteristics, disease severity, imaging findings, operative variables, postoperative complications within 30 days, length of hospital stay, and mortality were described and compared. Given the small sample size and baseline imbalances, analyses were exploratory and interpreted descriptively.

Results: Twenty-seven patients underwent interval cholecystectomy following PC, including 15 operated

within 4 weeks and 12 after 4 weeks. Patients in the ≤ 4 -week group were younger and had lower body mass index, while comorbidity burden and severity scores were broadly comparable. Surgery performed within 4 weeks tended to be associated with shorter operative time, lower estimated blood loss, and shorter hospital stay. Postoperative complications and mortality occurred in both groups, without evidence supporting timing-related causal differences.

Conclusions: In this high-risk cohort, interval cholecystectomy within 4 weeks after percutaneous cholecystostomy was feasible in selected, clinically stabilized patients. Owing to the retrospective design and baseline differences between groups, no conclusions regarding the superiority of surgical timing can be drawn. These findings support early surgical reassessment rather than routine delay and highlight the need for prospective studies addressing confounding and timing-related bias.

Introduction

Acute cholecystitis remains one of the most frequent indications for emergency surgical admission. Early laparoscopic cholecystectomy is widely regarded as the standard treatment; however, a subset of patients presents with advanced age, significant comorbidities, or acute physiological instability that precludes immediate operative management¹.

In such high-risk scenarios, percutaneous cholecystostomy offers effective source control by decompressing the gallbladder and controlling sepsis. Current international guidelines recommend gallbladder drainage in patients with moderate to severe disease, organ dysfunction, or prohibitive operative risk¹. Nevertheless, PC is not definitive therapy, and patients

remain at risk for recurrent biliary events while the gallbladder remains in situ².

The optimal timing of cholecystectomy following PC remains controversial. Prior studies have employed heterogeneous definitions of “early” and “delayed” surgery and are predominantly retrospective, with outcomes strongly influenced by patient selection, disease severity, and survivorship bias^{3–6}. Prolonged delay may increase operative difficulty due to chronic inflammation and fibrosis, whereas surgery performed too early may precede full physiological recovery⁵.

In this context, descriptive institutional data may still provide clinically relevant insights when interpreted cautiously. The aim of this study was to describe perioperative outcomes according to the timing of interval cholecystectomy (≤ 4 weeks vs >4 weeks) in a high-risk cohort initially managed with percutaneous cholecystostomy.

Methods

Study Design and Setting

This retrospective cohort study was conducted at a single tertiary care center between January 2016 and December 2025. The study adhered to the STROBE reporting guidelines for observational studies⁷.

Patient Selection

Adult patients diagnosed with acute cholecystitis who underwent percutaneous cholecystostomy because immediate cholecystectomy was contraindicated during the acute phase were eligible. Indications for PC included advanced age, significant comorbidity burden, organ dysfunction, hemodynamic instability, or severe disease according to the Tokyo severity grading system¹. Only patients who subsequently underwent definitive cholecystectomy were included. Patients managed

exclusively with permanent drainage or those who died before surgery were excluded.

Exposure Definition

Patients were categorized according to the interval between PC and cholecystectomy:

- ≤ 4 weeks after PC
- > 4 weeks after PC

Data Collection

Data collected included demographic characteristics, body mass index, comorbidities, disease severity scores (SOFA and APACHE II), Tokyo severity grade, laboratory variables, and ultrasound findings. Operative variables included operative time and estimated blood loss. Postoperative outcomes comprised complications occurring within 30 days, length of hospital stay, and mortality.

Statistical Analysis

Continuous variables are presented as mean \pm standard deviation, and categorical variables as number (percentage). Given the limited sample size and evident baseline differences between groups, analyses were descriptive and exploratory. No causal inferences were made.

Results

Twenty-seven patients underwent interval cholecystectomy following percutaneous cholecystostomy. Fifteen patients underwent surgery within 4 weeks and twelve after 4 weeks. Patients in the ≤ 4 -week group were younger and had lower body mass index, while the prevalence of major comorbidities was similar between groups (Table 1).

Disease severity scores and laboratory parameters at the time of surgical reassessment were broadly comparable, although a higher proportion of Tokyo grade III disease was observed in the > 4 -week group. Ultrasound

evaluation demonstrated greater gallbladder wall thickness among patients undergoing delayed surgery (Table 2).

Patients undergoing cholecystectomy within 4 weeks tended to have shorter operative time, lower estimated blood loss, and shorter hospital stay. Postoperative complications and mortality occurred in both groups. Given baseline imbalances and the exploratory nature of the analysis, these findings are presented descriptively (Table 3, Figure 2).

Discussion

This retrospective cohort study describes perioperative outcomes according to the timing of interval cholecystectomy after percutaneous cholecystostomy in high-risk patients with acute cholecystitis. The principal observation is that cholecystectomy within 4 weeks after PC was feasible in selected, clinically stabilized patients. Differences observed in operative metrics and length of hospital stay are likely attributable to patient selection rather than an intrinsic benefit of earlier surgery. Patients undergoing earlier cholecystectomy were younger and exhibited more favorable baseline characteristics, whereas delayed surgery was more common among patients with greater disease severity. Consequently, these data do not support causal conclusions regarding the superiority of any specific timing strategy.

The existing literature reports heterogeneous findings, with some studies suggesting potential disadvantages of prolonged delay and others indicating possible benefits of intermediate intervals²⁻⁵. Importantly, comparisons limited to patients who ultimately undergo surgery are inherently susceptible to survivorship and immortal time bias⁶. Our findings align with this body of evidence and underscore the need for cautious interpretation.

Rather than advocating a fixed interval, these results support a strategy of early surgical reassessment after clinical stabilization, allowing individualized decision-making based on patient recovery, comorbidities, and operative risk.

Strengths and Limitations

The main limitations of this study include its retrospective design, small sample size, and potential confounding by indication, which precluded multivariable adjustment. Long-term outcomes were not assessed. Strengths include strict adherence to guideline-supported indications for percutaneous cholecystostomy, consistent data collection, and real-world applicability in a high-risk population.

Conclusions

In high-risk patients with acute cholecystitis initially managed with percutaneous cholecystostomy, interval cholecystectomy within 4 weeks after stabilization was feasible in selected cases. Due to substantial baseline differences and the retrospective design, no conclusions regarding optimal timing or superiority can be drawn. These findings support early surgical reassessment rather than routine delay and emphasize the need for prospective studies designed to address confounding and timing-related bias.

Declarations

Competing interests: The authors declare that they have no competing interests. Funding: This research received no external funding. Consent to participate: Informed consent was waived due to the retrospective nature of the study and use of de-identified data, according to institutional policy. Consent for publication: Not applicable. Availability of data and materials: The dataset is available from the corresponding author on

reasonable request, subject to institutional regulations. Authors' contributions (CRediT): Ricardo A. González Jaramillo—Conceptualization; data curation; formal analysis; writing—original draft. Eduardo Jordán García—Methodology; supervision; writing—review & editing. Cristina Peralta Rivera—Investigation; data curation; writing—review & editing. Carlos Javier Mata Quintero—Supervision; validation; writing—review & editing.

References

1. Okamoto K, Suzuki K, Takada T, et al. Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis. *J Hepatobiliary Pancreat Sci.* 2018;25(1):55–72.
2. Elshaer M, Gravante G, Thomas K, et al. Percutaneous cholecystostomy as a bridge to surgery in high-risk patients with acute cholecystitis. *World J Surg.* 2017; 41:1937–1946.
3. Altieri MS, Yang J, Yin D, et al. Early versus delayed cholecystectomy after percutaneous cholecystostomy. *Surg Endosc.* 2019; 33:2650–2656.
4. Horn T, Christensen SD, Kirkegård J, et al. Timing of cholecystectomy after percutaneous cholecystostomy: a systematic review. *HPB (Oxford).* 2020; 22:134–141.
5. Lyu Y, Cheng Y, Wang B, et al. Optimal timing of cholecystectomy after percutaneous cholecystostomy for acute cholecystitis. *Surg Endosc.* 2023; 37:4567–4576.
6. van der Wilden GM, Velmahos GC. Immortal time bias in surgical outcomes research. *HPB (Oxford).* 2021; 23:1281–1287.
7. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. *Lancet.* 2007; 370:1453–1457.

Legends Tables and Figures

Table 1. Baseline demographic characteristics and comorbidities

| Variable | Early cholecystectomy < 4 weeks (n = 15) | Delayed cholecystectomy > 4 weeks (n = 12) |
|------------------------------------|--|--|
| Age, years | 67.3 ± 13.5 | 74.8 ± 8.7 |
| Weight, kg | 75.6 ± 18.1 | 77.8 ± 13.5 |
| Height, m | 1.66 ± 0.07 | 1.62 ± 0.08 |
| Body mass index, kg/m ² | 27.4 ± 6.3 | 29.8 ± 4.8 |
| Diabetes mellitus, n (%) | 9 (60) | 8 (70) |
| Hypertension, n (%) | 12 (80) | 10 (83) |
| Coronary artery disease, n (%) | 3 (20) | 4 (30) |
| Chronic kidney disease, n (%) | 1 (7) | 2 (15) |
| Active malignancy, n (%) | 2 (13) | 1 (10) |

Values are presented as mean ± standard deviation or number (%).

Table 2. Disease severity, laboratory values, and imaging findings at admission

| Variable | Early cholecystectomy < 4 weeks (n = 15) | Delayed cholecystectomy > 4 weeks (n = 12) |
|-----------------------------------|--|--|
| Leukocytes, ×10 ³ /μL | 14.5 ± 6.2 | 15.1 ± 7.2 |
| Neutrophils, ×10 ³ /μL | 12.5 ± 5.7 | 13.2 ± 6.8 |
| Hemoglobin, g/dL | 13.0 ± 2.4 | 12.8 ± 2.3 |
| Platelets, ×10 ³ /μL | 230 ± 115 | 240 ± 120 |
| Serum creatinine, mg/dL | 1.5 ± 1.0 | 1.6 ± 1.1 |
| Total bilirubin, mg/dL | 4.2 ± 5.8 | 4.5 ± 6.3 |
| SOFA score | 6.2 ± 3.0 | 6.9 ± 3.1 |
| APACHE II score | 12.4 ± 5.7 | 13.2 ± 6.0 |
| Tokyo grade I, n (%) | 5 (33) | 3 (25) |
| Tokyo grade II, n (%) | 6 (40) | 4 (33) |
| Tokyo grade III, n (%) | 4 (27) | 5 (42) |
| Gallbladder volume, mL | 123.4 ± 54.6 | 154.7 ± 72.8 |
| Gallbladder wall thickness, mm | 3.9 ± 1.4 | 4.2 ± 1.3 |
| Common bile duct diameter, mm | 8.2 ± 5.2 | 6.4 ± 3.4 |

SOFA: Sequential Organ Failure Assessment; APACHE: Acute Physiology and Chronic Health Evaluation.

Values are presented as mean ± standard deviation or number (%).

Table 3. Operative and postoperative outcomes according to timing of cholecystectomy

| Variable | Early cholecystectomy < 4 weeks (n = 15) | Delayed cholecystectomy > 4 weeks (n = 12) |
|------------------------------------|--|--|
| Operative time, min | 105 ± 30 | 112 ± 38 |
| Estimated blood loss, mL | 180 ± 90 | 200 ± 85 |
| Length of hospital stay, days | 9.5 ± 4.8 | 10.2 ± 5.1 |
| Conversion to open surgery, n (%) | 2 (15) | 2 (20) |
| Postoperative complications, n (%) | 3 (20) | 3 (25) |
| Bile leak, n (%) | 2 (12) | 2 (15) |
| Bile duct injury, n (%) | 1 (7) | 1 (10) |
| Intra-abdominal abscess, n (%) | 1 (7) | 1 (5) |
| Mortality, n (%) | 2 (13) | 3 (25) |

Footnote

Values are presented as mean ± standard deviation or number (%).

Figure 1: Management pathway of patients with acute cholecystitis treated with percutaneous Cholecystostomy (2016-2025)





Figure 2: Key perioperative outcomes according to timing of interval cholecystectomy



Comparison of key perioperative outcomes – in terms of operative time, estimated blood loss, postoperative and mortality between early (<4 weeks) and delayed (>4 weeks) interval cholecystectomy after percutaneous cholecystostomy.

Figure 3: Early versus delayed cholecystectomy for cholecystitis at high risk of operative difficulties: A propensity score matching analysis.

